HUDSON, Mass. and YOKNEAM ILLIT, Israel, July 07, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd . (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio...
Veteran physician , medical affairs and clinical research leader brings 30 years of rehabilitation medicine experience and deep expertise in neuroscience , mobility technologies , and metabolic...
Oramed strategic transaction successfully closed and $10 million financing received Oratech acquisition brings $6. 5 million in cash and promising Protein Oral Delivery...
HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio...
Global data since 2013 show just 3% lifetime fracture prevalence, declining to 0.3% over the past six y ears Zero fractures reported across 97 German users since 2018 , spanning broad patient...
HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform...
HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform...
Advancing t ransformation into a d iversified b iomedical i nnovation c ompany with a c lear p ath to c ash f low p ositiv e Oramed s trategic t ransaction ...